Profiles - Executive team and Regeneus scientists
Dr. Graham Vesey leads the executive team. He brings to Regeneus a proven track record in building business around new technology.
Prior to joining Regeneus, Dr. Vesey co founded BTF Pty. Ltd. Over an eight year period Dr. Vesey and the BTF team developed a suite of unique biological products and grew significant international sales. BTF became one of Australia’s fastest growing companies.
The success of BTF by international standards is stellar. In 2007 the French diagnostic company BioMerieux acquired BTF. BioMerieux is established in 150 countries, with 35 subsidiaries and an extensive network of distributors. Few Australian biotechnology companies achieve this goal in such a short time span.
Dr. Vesey is also well recognised for his scientific expertise and his ability to develop and commercialise intellectual property. He is an inventor on 17 international patents and has published over 50 scientific papers.
John is an experienced director, chief executive, corporate adviser and lawyer. John has been a director of, advised and worked with emerging biotechnology companies for over ten years. He was a co-founder and former executive director of Proteome Systems where he had responsibility for business and corporate development and legal affairs.
John was an adviser to and non-executive director of BTF. He was the former MD and CEO of Primelife Corporation and Babcock & Brown Communities (now known as Lend Lease Primelife), the largest ASX listed owner, operator and developer of retirement and aged care facilities in Australia. John is a former partner of Allens and was head of the corporate practice. At Allens, he specialised in mergers and acquisitions, fundraising, and corporate and commercial advice across a wide range of industries.
Pierre is responsible for equine sales and marketing development. Pierre is a specialist in sales and marketing strategies for start ups. This includes brand development, positioning, channel to market and distribution.
Pierre has a 15 year history in business management and market development, with extensive experience in building products and solar energy industries. Prior to joining Regeneus Pierre was responsible for setting up the Australian based subsidiary of Umicore, a world leading company in architectural products. He has successfully led teams in Europe, South East Asia and Pacific regions.
Pierre is a passionate advocate of environment protection, sustainability and animal welfare. He is totally committed to his 6 horses and 3 dogs.
Rebecca manages the Regeneus Applied Research Programme, as well as clinical trials for new products.
Prior to joining Regeneus, Rebecca was a veterinary nurse. She brings 15 years of experience in veterinary medicine. Rebecca has also acquired international experience in her capacity as liaison officer for world leading organisations in the protection of sea turtles. She has lived in Greece and Guatemala.
Associate Professor Ben Herbert, Macquarie University, leads the Regeneus research program. Dr. Herbert manages a team of researchers and Ph.D. students. His team focuses on new techniques to harness the regenerative capabilities of adult stem cells.
Dr. Herbert is also Director of the Proteomics Technology Centre of Expertise at UTS. In 1999 he co founded Proteome Systems Ltd., where he worked for seven years. During this time Proteome Systems was listed on the Australian Securities Exchange (PXL).
He also played a key role in establishing the Australian Proteome Analysis Facility (APAF) at Macquarie University. Dr. Herbert was responsible for the development of a range of products in association with the U.S. multinational Bio-Rad.
Dr. Herbert has developed and patented intellectual property centred on novel methods for protein extraction, sample preparation, fractionation and electrophoresis. At Macquarie University, he developed and patented a range of instruments and devices for electrophoresis.
At Proteome Systems he was responsible for developing a new IP portfolio for the commercialisation of the sample preparation and electrophoresis products.
Professor Marc Wilkins is a non executive director of Regeneus.
Marc is Professor of Systems Biology at the University of New South Wales (UNSW). In 1999 he co founded the biotechnology company Proteome Systems. He was Vice President of Bioinformatics (1999-2004), and then Head of Proteomics (2004-2005). Marc established and managed the company’s Global Strategic Alliance with IBM as a channel to market. He was responsible for bioinformatics research and development inside the company. The output was commercialised into the BioinformatIQ platform.
Marc currently serves on scientific advisory boards for the ARC Centre of Excellence in Bioinformatics, the Australian Proteomics Computing Facility (APCF), the UNSW Biomolecular Mass Spectrometry Facility (BMSF), and the Ramaciotti Centre for Gene Function Analysis.
Additionally, he is an editor of PROTEOMICS journal. He lectures in the area of proteomics, biochemistry and biotechnology commercialisation. Marc developed the concept of the proteome and coined the term. His seminal publications on proteomics, including co authoring and co editing the first book on the subject, were major contributors to the establishment of the field of proteome research. Proteome research is now a major international field of endeavour.